Advances in Investigational pharmacology and therapeutic medicine
Esam Z. Dajani Ph.D.


Loyola University


Journal Short Name-APTM


Professor Esam Z. Dajani, Ph.D., FACG is the founder and president of International Drug Development Consultants (IDDC) Corporation, a Contract Research Organization (CRO) which provides scientific consulting services to pharmaceutical companies, law firms and governmental agencies. The scope of the consulting service includes clinical pharmacology, toxicology, drug development and regulatory affairs.  He has directed worldwide clinical research and development at major pharmaceutical companies. He led the research teams that discovered and developed misoprostol (Cytotec), an anti-ulcer drug.  Since 1980, he held continuous academic appointments in pharmacology and in medicine.  He is currently serving as Adjunct Professor of Medicine at Loyola University-Chicago.   He taught pharmacology and toxicology to medical, dental and pharmacy students.  He has research interests in clinical pharmacology, gastrointestinal pharmacology, central nervous system pharmacology, prostaglandins, non-steroidal anti-inflammatory drugs (NSAIDs), growth hormones (e.g., epidermal growth factor), cannabinoids and narcotic analgesics.  

Reasearch Interest

Pre-clinical and Clinical Pharmacology; Toxicology; Drug Development and Regulatory Affairs; Contract Research Organizations (CROs); Professor Dajani expert witness consulting practice provides investigations, research, record analysis, consultation, merit statement, and testimony.



Email :  [email protected]

Signup to recive email updatesx